OBI Pharma
OBI Pharma, Inc., a clinical stage oncology company, research and develops novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. The company's pipeline products include Adagloxad simolenin which is in phase 3 for the treatment of triple-negative breast cancer; OBI-833 that is in phase 2 for the treatment of non-small cell lung cancer; OBI-3424 which has co… Read more
OBI Pharma - Asset Resilience Ratio
OBI Pharma (4174) has an Asset Resilience Ratio of 17.59% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how OBI Pharma's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down OBI Pharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 0% |
| Short-term Investments | NT$673.70 Million | 17.59% |
| Total Liquid Assets | NT$673.70 Million | 17.59% |
Asset Resilience Insights
- Good Liquidity Position: OBI Pharma maintains a healthy 17.59% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
OBI Pharma Industry Peers by Asset Resilience Ratio
Compare OBI Pharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for OBI Pharma (2011–2024)
The table below shows the annual Asset Resilience Ratio data for OBI Pharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.74% | NT$1.40 Billion | NT$5.65 Billion | -8.86pp |
| 2023-12-31 | 33.60% | NT$1.88 Billion | NT$5.60 Billion | +33.13pp |
| 2022-12-31 | 0.47% | NT$31.46 Million | NT$6.63 Billion | -2.69pp |
| 2021-12-31 | 3.16% | NT$141.77 Million | NT$4.49 Billion | -4.02pp |
| 2020-12-31 | 7.18% | NT$383.53 Million | NT$5.34 Billion | +7.16pp |
| 2019-12-31 | 0.02% | NT$1.39 Million | NT$5.66 Billion | -38.95pp |
| 2017-12-31 | 38.97% | NT$2.02 Billion | NT$5.19 Billion | +1.68pp |
| 2016-12-31 | 37.29% | NT$2.36 Billion | NT$6.33 Billion | +4.71pp |
| 2012-12-31 | 32.58% | NT$284.81 Million | NT$874.17 Million | -41.39pp |
| 2011-12-31 | 73.97% | NT$386.65 Million | NT$522.72 Million | -- |